Macular vitelliform lesion in desferrioxamine-related retinopathy.
To report a case of a macular vitelliform lesion associated with desferrioxamine treatment. Ocular, electrophysiological, psychophysical, perimetric, fluorescein angiographic, fundus autofluorescence, and spectral-domain OCT examinations were obtained on a 45-year-old Caucasian woman with thalassemia major treated with blood transfusions and desferrioxamine. The patient was observed to have a vitelliform macular lesion in the right eye with a hypopigmented macular lesion and retinal pigment mottling in the left. At the most recent follow-up visit, best-corrected visual acuity was 20/70 in the right eye and 20/25 in left. Full-field electroretinogram (ERG) testing showed normal cone and rod responses. Mild localized elevations of rod psychophysical thresholds were found. A vitelliform macular lesion can develop in patients treated with desferrioxamine. Some such patients may not show diffuse photoreceptor cell functional loss as determined by electrophysiological testing.
Department of Ophthalmology and Visual Sciences (MC 648), University of Illinois at Chicago, Room 3.85, Eye and Ear Infirmary, 1855 W Taylor Street, Chicago, IL 60612-7234, USA.
Mohamed A
MA
Genead
Gerald A
GA
Fishman
Anastasios
A
Anastasakis
Martin
M
Lindeman
D003676:Deferoxamine / Q000009:adverse effects*; D004596:Electroretinography; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D008875:Middle Aged; D012164:Retinal Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D017262:Siderophores / Q000009:adverse effects*; D014792:Visual Acuity; D058609:Visual Field Tests; D014794:Visual Fields / Q000502:physiology; D017086:beta-Thalassemia / Q000188:drug therapy
D017262:Siderophores; D003676:Deferoxamine